BMJ will require authors to disclose clinical trial data

Share this article:
Starting next year, the BMJ will not publish academic papers on drugs or devices unless the relevant anonymized patient-level data are made available for third-party study.
The medical journal, which announced the new policy yesterday, will require this commitment for all clinical trials of drugs and devices—whether industry funded or not—beginning in January 2013.
In an editorial about the requirement, BMJ's Fiona Godlee, editor in chief, said that the fact that such data are kept private has made it harder to assess drug safety and efficacy.
The journal's show of publishing power is the latest move to try and get drugmakers to take the wraps off data.
Earlier this year, Cochrane Collaboration researchers, attempting to write a systematic analysis of the drug Tamiflu, accused Roche of reporting biases in the trial program for the drug.
When patient-level clinical research data—the detailed data that sit behind the results of clinical trials—are made available for independent scrutiny, academics and companies say, patients and providers can make better treatment decisions about drugs.
While this data is often withheld by industry, for ostensibly competitive reasons, some have pledged to open up. Medtronic, faced with controversy over a product, pledged to release all relevant clinical research data into the public domain in a partnership with Yale University.
And GlaxoSmithKline, which has also faced controversy on its drugs such as Avandia, this month said that it would make such data available from its trials.
In a statement today about the BMJ commitment on clinical trial transparency, GSK's Patrick Vallance, president, pharmaceuticals R&D, noted, “Moves like this should help medical research by allowing scientists to study the detailed results of clinical trials and increase understanding of current and new medicines. Ultimately this should improve patient care.”
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...